| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/20/2008 | US20080070935 Isoquinoline, Quinazoline and Phthalazine Derivatives |
| 03/20/2008 | US20080070933 Purine, Pyrimidine, and Azaindole Derivatives |
| 03/20/2008 | US20080070930 2-(4-oxo-4,5,6,7-tetrahydroindol-1-yl) or 2-(4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl) pyrimidines or pyrazines; cancer, inflammation, arthritis, angiogenesis, fungal, viral and Plasmodium infections; Heat Shock Protein 90 inhibitors |
| 03/20/2008 | US20080070918 Heat Shock Protein-90 (HSP-90) inhibitors; cancer, inflammation, arthritis, angiogenesis, antimalaria, fungal and viral infections; 2-(4-Hydroxy-cyclohexylamino)-4-(3,7,7-trimethyl-5-oxo-5,6,7,8-tetrahydro-4H-cinnolin-1-yl)-benzamide for example; synthesis from corresponding benzonitriles |
| 03/20/2008 | US20080070916 Treating disorders such as proliferative diseases, and cancer; compounds can act as probes of biological function; libraries; for example, 2-ethoxy-3-(2-hydroxyethoxyethoxyethyl)-4-(1-acetylindol-3-yl)-6-(morpholinocarbonyl)-2H-3,4-dihydropyran |
| 03/20/2008 | US20080070907 Substituted chiral fused [1,2] imidazo [4,5-C] ring compounds and methods |
| 03/20/2008 | US20080070906 Quinolinone derivatives |
| 03/20/2008 | US20080070905 An enzyme in the tryptophan degradation pathway, used to treat neurodegenerative disorders, certain cancers, drug addiction; 2-sulfonamido-substituted oxazole, imidazole or thiazole compounds such as 3,4-dimethoxy-N-[4-(3-nitrophenyl)-5-dimethylaminomethyl-1,3-thiazole-2-yl]benzenesulfonamide |
| 03/20/2008 | US20080070897 Having high bioavailability levels and reduced variability of bioavailability by use of dispersed, colloidal structures, colloids or analogous structures of the drug, a hydrophilic component (ethanol) , a surfactant such as polyglycerol, polyoxyethylene castor oil |
| 03/20/2008 | US20080070894 Anticancer agents; PLK1 inhibitors; PLK=polo-like kinase; imidazo(1,2-a)pyridines such as 5-bromo-4-[8-(difluoromethyl)imidazo[1,2-a]pyridin-3-yl]-N-[(1S)-1-phenylethyl]-2-pyrimidinamine |
| 03/20/2008 | US20080070893 Cancer, neurological disorders, autoimmune disorders; inhibitors of CK2, a serine/threonine kinase; based upon macrocyclic pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine compounds |
| 03/20/2008 | US20080070886 Anti-cancer combinations |
| 03/20/2008 | US20080070881 Prostate Cancer Treatment |
| 03/20/2008 | US20080070869 Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators |
| 03/20/2008 | US20080070864 Modulating the activity of farnesoid X receptor (FXR) and/or orphan nuclear receptors; N-[3-(2,4-dimethylphenyl)-4-oxo-3,4-dihydroquinazolin-2-ylmethyl]benzenesulfonamide |
| 03/20/2008 | US20080070859 Treats neoplastic disorders, infections from fungal or fungal-like organisms and other parasites |
| 03/20/2008 | US20080070857 Comprises a substance that inhibits expression of macrophage migration inhibitory factor (MIF) such as siRNA of MIF; adenocarcinoma or colon cancer |
| 03/20/2008 | US20080070849 Synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan |
| 03/20/2008 | US20080070848 Anti-cancer combinations |
| 03/20/2008 | US20080070847 Administering 5,6-dimethylxanthenone-4-acetic acid and and administering a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors for therapy of cancer |
| 03/20/2008 | US20080070843 Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics |
| 03/20/2008 | US20080070839 Composition and method for treating cancer |
| 03/20/2008 | US20080070836 Zinc transporter LIV1 can be used as an epithelial-mesenchymal transition (EMT) regulatory agent; further, because EMT is involved in cancer progression, LIV1 antisense nucleotides and the like may be used as pharmaceuticals for treating cancer |
| 03/20/2008 | US20080070835 Hla-Dr-Binding Antigen Peptide Derived From Wt1 |
| 03/20/2008 | US20080070305 Inhibition of expression of a target gene |
| 03/20/2008 | US20080070279 Group of Synthetic Antimicrobal Peptides |
| 03/20/2008 | US20080070259 Using presence or absence of mutation in metalloenzyme polynucleotides as diagnostic indicator of cardiovascular and neurodegenerative disorders |
| 03/20/2008 | US20080070258 Polyamide nucleic acid derivatives and agents, and processes for preparing them |
| 03/20/2008 | US20080069904 Inhibition of angiogenesis through nitric oxide tachyphylaxis |
| 03/20/2008 | US20080069901 Using cisplatin; therapy for bone or liver cancer; oral bioavailable |
| 03/20/2008 | US20080069900 Combination chemotherapy compositions and methods |
| 03/20/2008 | US20080069899 In mixture with drug that prevents Dna reproduction |
| 03/20/2008 | US20080069896 Side effect reduction; reduced toxicity; fine particle size; blend of platinum chloride or chloroplatinic acid with apatite |
| 03/20/2008 | US20080069868 Irinotecan Preparation |
| 03/20/2008 | US20080069866 Immunotherapeutic methods and compositions |
| 03/20/2008 | US20080069863 Device for treatment of disorders in the oral cavity with nitric oxide, and manufacturing process for the same |
| 03/20/2008 | US20080069861 Gastrointestinal health |
| 03/20/2008 | US20080069844 Mucosal Vaccine Adjuvants Containing Bacterial Flagellins as an Active Component |
| 03/20/2008 | US20080069841 Pharmaceutical Compositions Containing Botulinum Neurotoxin A2 |
| 03/20/2008 | US20080069840 Immunotherapy ; antigen codes Dna vaccine; antitumor agents |
| 03/20/2008 | US20080069837 Composition and method for treating cancer using herpes virus |
| 03/20/2008 | US20080069817 Heteroaryl-fused pyrimidinyl compounds as anticancer agents |
| 03/20/2008 | US20080069816 Carcinoembryonic antigen (CEA); utilizes crystallographic structural data to select immunoglobulin framework having maximum structural overlap non-human donor molecule |
| 03/20/2008 | US20080069812 Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents |
| 03/20/2008 | US20080069809 Administering ingenol angelate to treat cancer cells having high protein kinase C (PKC) activity; myeloid leukiemia |
| 03/20/2008 | US20080069795 Depleting T cells in the patient prior to a administration of a platinum-containing compound |
| 03/20/2008 | US20080069775 Administering anti-idiotype antibody or antibody fragment comprising heavy chain variable region sequences and light chain variable region sequences conjugated to a soluble immunogenic carrier protein |
| 03/20/2008 | US20080069772 Treatment of transformed or infected biological cells |
| 03/20/2008 | DE102007037830A1 Indolinsulfonamidverbindungen Indolinsulfonamidverbindungen |
| 03/20/2008 | DE102006041382A1 Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren Carbamoyl-sulphoximides as protein kinase inhibitors |
| 03/20/2008 | DE102006030479A1 Indazolderivate Indazole derivatives |
| 03/20/2008 | DE10080167B4 Medikament zur Hemmung der Expression eines vorgegebenen Gens Medicament for inhibiting the expression of a given gene |
| 03/20/2008 | CA2663474A1 Pro-oxidant anti-cancer compounds |
| 03/20/2008 | CA2663376A1 N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
| 03/20/2008 | CA2663279A1 Use of 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,-4-dioxo-3,4-dihydro-2h-pyridimin-1-ylmethyl-4-fluoro-benzonitrile for treating diabetes, cancer,autoimmune disorders and hiv infection |
| 03/20/2008 | CA2663234A1 Novel phenylacetic acid derivative |
| 03/20/2008 | CA2663132A1 Acetylenic compounds |
| 03/20/2008 | CA2662937A1 Multi-functional small molecules as anti-proliferative agents |
| 03/20/2008 | CA2662737A1 The preparation and the use of ethoxy combretastatins and their prodrugs |
| 03/20/2008 | CA2662617A1 Quinazoline based egfr inhibitors containing a zinc binding moiety |
| 03/20/2008 | CA2662554A1 Compounds for the treatment of angiogenesis |
| 03/20/2008 | CA2662432A1 Combinations of class-i specific histone deacetylase inhibitors with proteasome inhibitors |
| 03/20/2008 | CA2661938A1 Pyrimidines derivatives and their use as kinase inhibitors |
| 03/20/2008 | CA2660987A1 Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors |
| 03/20/2008 | CA2659070A1 Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors |
| 03/19/2008 | EP1900827A2 Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia |
| 03/19/2008 | EP1900816A2 GL50 molecules and uses therefor |
| 03/19/2008 | EP1900815A2 In vivo production of small interfering RNAs that mediate gene silencing |
| 03/19/2008 | EP1900753A2 Method of administering therapeutic polypeptides, and polypeptides therefor |
| 03/19/2008 | EP1900746A1 Versipelostatin derivative, anti-cancer agent and processes for production of the derivative and agent |
| 03/19/2008 | EP1900742A1 Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof |
| 03/19/2008 | EP1900738A2 Substituted pyrroline kinase inhibitors |
| 03/19/2008 | EP1900729A1 Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors |
| 03/19/2008 | EP1900377A1 Inhibitors of GPR87 for cancer therapy |
| 03/19/2008 | EP1900375A1 Calreticulin for its use as a medication for the treatment of cancer in a mammal |
| 03/19/2008 | EP1900360A1 Homer a new target of treating psychiatric disorders |
| 03/19/2008 | EP1899379A2 Cd19 antibodies and their uses |
| 03/19/2008 | EP1899348A1 Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
| 03/19/2008 | EP1899346A1 Pyrrolotriazine compounds useful as kinase inhibitors |
| 03/19/2008 | EP1899345A1 Pyrrolotriazine compounds useful as kinase inhibitors |
| 03/19/2008 | EP1899335A1 Pyrroloquinoline derivatives and their use as protein kinase inhibitors |
| 03/19/2008 | EP1899330A1 Substituted glycinamides having an antithrombotic and factor xa-inhibiting effect |
| 03/19/2008 | EP1899329A1 Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors |
| 03/19/2008 | EP1899325A1 Imidazolinone and hydantoine derivatives as novel inhibitors of histone deacetylase |
| 03/19/2008 | EP1899323A2 Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
| 03/19/2008 | EP1899320A1 SUBSTITUTED PYRR0LIDIN-2-0NES , PIPERIDIN-2-0NES AND ISOTHIAZOLIDINE-1, 1-DIOXIDES, THEIR USE AS KVl .5 POTASSIUM CHANNEL BLOCKERS AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM |
| 03/19/2008 | EP1899316A1 Benzopyranone compounds for treating cancer |
| 03/19/2008 | EP1899315A1 Benzofuranone derivatives as nonsteroidal progesterone receptor modulators |
| 03/19/2008 | EP1898936A1 Method of cancer treatment using sirna silencing |
| 03/19/2008 | EP1898920A1 Formulation comprising farnesyl dibenzodiazepinone and a pharmaceutically acceptable surfactant |
| 03/19/2008 | EP1898918A1 Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators |
| 03/19/2008 | EP1898917A1 Aminopyrimidines as kinase modulators |
| 03/19/2008 | EP1898916A2 Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer |
| 03/19/2008 | EP1898912A1 Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| 03/19/2008 | EP1898899A1 Inhibitors of fibroblast activation protein alpha |
| 03/19/2008 | EP1711174B1 Adjuvant compositions |
| 03/19/2008 | EP1660487B1 Pyrrole compositions useful as inhibitors of c-met |
| 03/19/2008 | EP1562933B1 Substituted amine derivatives and methods of use in the treatment of angiogenesis related disorders |
| 03/19/2008 | EP1530573B1 Condensed heterocyclic pyrazole derivatives as kinase inhibitors |
| 03/19/2008 | EP1519683A4 Solid hydrogel coupling for ultrasound imaging and therapy |